Tenofovir alafenamide for HIV infection: is less more?
Publication
, Journal Article
Wyatt, C; Baeten, JM
Published in: Lancet
June 27, 2015
Duke Scholars
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
June 27, 2015
Volume
385
Issue
9987
Start / End Page
2559 / 2560
Location
England
Related Subject Headings
- Thiazoles
- Tenofovir
- Quinolones
- Organophosphonates
- Male
- Humans
- HIV Infections
- General & Internal Medicine
- Female
- Emtricitabine
Citation
APA
Chicago
ICMJE
MLA
NLM
Wyatt, C., & Baeten, J. M. (2015). Tenofovir alafenamide for HIV infection: is less more? Lancet, 385(9987), 2559–2560. https://doi.org/10.1016/S0140-6736(15)60725-5
Wyatt, Christina, and Jared M. Baeten. “Tenofovir alafenamide for HIV infection: is less more?” Lancet 385, no. 9987 (June 27, 2015): 2559–60. https://doi.org/10.1016/S0140-6736(15)60725-5.
Wyatt C, Baeten JM. Tenofovir alafenamide for HIV infection: is less more? Lancet. 2015 Jun 27;385(9987):2559–60.
Wyatt, Christina, and Jared M. Baeten. “Tenofovir alafenamide for HIV infection: is less more?” Lancet, vol. 385, no. 9987, June 2015, pp. 2559–60. Pubmed, doi:10.1016/S0140-6736(15)60725-5.
Wyatt C, Baeten JM. Tenofovir alafenamide for HIV infection: is less more? Lancet. 2015 Jun 27;385(9987):2559–2560.
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
June 27, 2015
Volume
385
Issue
9987
Start / End Page
2559 / 2560
Location
England
Related Subject Headings
- Thiazoles
- Tenofovir
- Quinolones
- Organophosphonates
- Male
- Humans
- HIV Infections
- General & Internal Medicine
- Female
- Emtricitabine